San Diego, CA, USA - June 4, 2018 - HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it is at a key stage in the company’s development of HBI-8000, HUYA’s lead novel epigenetic drug with important immunomodulatory properties. HUYA is conducting a Phase 2 trial of HBI-8000 in the US, investigating efficacy and safety in combination with nivolumab for the treatment of solid tumors.
